CN111297870B - 硝基苯甲酸类化合物在制备治疗肿瘤的药物中的应用 - Google Patents
硝基苯甲酸类化合物在制备治疗肿瘤的药物中的应用 Download PDFInfo
- Publication number
- CN111297870B CN111297870B CN202010203050.5A CN202010203050A CN111297870B CN 111297870 B CN111297870 B CN 111297870B CN 202010203050 A CN202010203050 A CN 202010203050A CN 111297870 B CN111297870 B CN 111297870B
- Authority
- CN
- China
- Prior art keywords
- nitrobenzoic acid
- tumors
- acid compounds
- cancer
- cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 25
- 239000003814 drug Substances 0.000 title claims abstract description 15
- 150000005338 nitrobenzoic acids Chemical class 0.000 title claims abstract description 15
- 229940079593 drug Drugs 0.000 title claims description 10
- 238000002360 preparation method Methods 0.000 title description 5
- 201000009546 lung large cell carcinoma Diseases 0.000 claims abstract description 11
- 206010023774 Large cell lung cancer Diseases 0.000 claims abstract description 10
- 201000001441 melanoma Diseases 0.000 claims abstract description 9
- 208000028830 lung neuroendocrine neoplasm Diseases 0.000 claims abstract description 5
- 206010006187 Breast cancer Diseases 0.000 claims description 6
- 208000026310 Breast neoplasm Diseases 0.000 claims description 6
- 206010052360 Colorectal adenocarcinoma Diseases 0.000 claims description 4
- 201000008808 Fibrosarcoma Diseases 0.000 claims description 4
- 201000007270 liver cancer Diseases 0.000 claims description 4
- 208000014018 liver neoplasm Diseases 0.000 claims description 4
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 4
- 206010041823 squamous cell carcinoma Diseases 0.000 claims description 4
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 3
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 3
- 201000002528 pancreatic cancer Diseases 0.000 claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims description 3
- 208000033383 Neuroendocrine tumor of pancreas Diseases 0.000 claims description 2
- 206010067517 Pancreatic neuroendocrine tumour Diseases 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 208000021010 pancreatic neuroendocrine tumor Diseases 0.000 claims description 2
- SLAMLWHELXOEJZ-UHFFFAOYSA-N 2-nitrobenzoic acid Chemical compound OC(=O)C1=CC=CC=C1[N+]([O-])=O SLAMLWHELXOEJZ-UHFFFAOYSA-N 0.000 claims 1
- 230000001472 cytotoxic effect Effects 0.000 abstract description 13
- -1 nitrobenzoic acid compound Chemical class 0.000 abstract description 9
- 125000004093 cyano group Chemical group *C#N 0.000 abstract description 2
- 229910052736 halogen Inorganic materials 0.000 abstract description 2
- 150000002367 halogens Chemical class 0.000 abstract description 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract description 2
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 abstract description 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract description 2
- 210000004027 cell Anatomy 0.000 description 32
- 230000000694 effects Effects 0.000 description 13
- 150000001875 compounds Chemical class 0.000 description 10
- 102100033350 ATP-dependent translocase ABCB1 Human genes 0.000 description 9
- 108010047230 Member 1 Subfamily B ATP Binding Cassette Transporter Proteins 0.000 description 9
- 108091006112 ATPases Proteins 0.000 description 7
- 102000057290 Adenosine Triphosphatases Human genes 0.000 description 7
- 239000000969 carrier Substances 0.000 description 5
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 5
- 229960004528 vincristine Drugs 0.000 description 5
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 5
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 4
- 201000011510 cancer Diseases 0.000 description 4
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 4
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
- 229930012538 Paclitaxel Natural products 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 238000012258 culturing Methods 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 201000005202 lung cancer Diseases 0.000 description 3
- 208000020816 lung neoplasm Diseases 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 229960001592 paclitaxel Drugs 0.000 description 3
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 3
- 210000004881 tumor cell Anatomy 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 206010009944 Colon cancer Diseases 0.000 description 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 2
- 229920002261 Corn starch Polymers 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 229930182555 Penicillin Natural products 0.000 description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
- 239000012980 RPMI-1640 medium Substances 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000008120 corn starch Substances 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 231100000782 microtubule inhibitor Toxicity 0.000 description 2
- 239000002480 mineral oil Substances 0.000 description 2
- 235000010446 mineral oil Nutrition 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 229940049954 penicillin Drugs 0.000 description 2
- 235000019271 petrolatum Nutrition 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 229960005322 streptomycin Drugs 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- LDVVTQMJQSCDMK-UHFFFAOYSA-N 1,3-dihydroxypropan-2-yl formate Chemical compound OCC(CO)OC=O LDVVTQMJQSCDMK-UHFFFAOYSA-N 0.000 description 1
- SGTNSNPWRIOYBX-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile Chemical compound C1=C(OC)C(OC)=CC=C1CCN(C)CCCC(C#N)(C(C)C)C1=CC=C(OC)C(OC)=C1 SGTNSNPWRIOYBX-UHFFFAOYSA-N 0.000 description 1
- LEACJMVNYZDSKR-UHFFFAOYSA-N 2-octyldodecan-1-ol Chemical compound CCCCCCCCCCC(CO)CCCCCCCC LEACJMVNYZDSKR-UHFFFAOYSA-N 0.000 description 1
- 206010000830 Acute leukaemia Diseases 0.000 description 1
- 208000010507 Adenocarcinoma of Lung Diseases 0.000 description 1
- 208000036832 Adenocarcinoma of ovary Diseases 0.000 description 1
- 208000010667 Carcinoma of liver and intrahepatic biliary tract Diseases 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 1
- 208000021309 Germ cell tumor Diseases 0.000 description 1
- 206010073069 Hepatic cancer Diseases 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 229940122255 Microtubule inhibitor Drugs 0.000 description 1
- 208000034176 Neoplasms, Germ Cell and Embryonal Diseases 0.000 description 1
- 206010052399 Neuroendocrine tumour Diseases 0.000 description 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 1
- 206010061534 Oesophageal squamous cell carcinoma Diseases 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061328 Ovarian epithelial cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 239000004264 Petrolatum Substances 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 206010041067 Small cell lung cancer Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- HVUMOYIDDBPOLL-XWVZOOPGSA-N Sorbitan monostearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XWVZOOPGSA-N 0.000 description 1
- 206010041834 Squamous cell carcinoma of skin Diseases 0.000 description 1
- 208000036765 Squamous cell carcinoma of the esophagus Diseases 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 229920002310 Welan gum Polymers 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 150000001558 benzoic acid derivatives Chemical class 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- 201000008275 breast carcinoma Diseases 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 230000022534 cell killing Effects 0.000 description 1
- 229940081733 cetearyl alcohol Drugs 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 208000030381 cutaneous melanoma Diseases 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000008387 emulsifying waxe Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 201000004101 esophageal cancer Diseases 0.000 description 1
- 208000007276 esophageal squamous cell carcinoma Diseases 0.000 description 1
- 208000021045 exocrine pancreatic carcinoma Diseases 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 230000031700 light absorption Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 201000002250 liver carcinoma Diseases 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 238000007422 luminescence assay Methods 0.000 description 1
- 201000005249 lung adenocarcinoma Diseases 0.000 description 1
- 201000005296 lung carcinoma Diseases 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 208000016065 neuroendocrine neoplasm Diseases 0.000 description 1
- 201000011519 neuroendocrine tumor Diseases 0.000 description 1
- 239000000346 nonvolatile oil Substances 0.000 description 1
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 1
- 208000013371 ovarian adenocarcinoma Diseases 0.000 description 1
- 201000006588 ovary adenocarcinoma Diseases 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 229940066842 petrolatum Drugs 0.000 description 1
- 229920001451 polypropylene glycol Polymers 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 201000003708 skin melanoma Diseases 0.000 description 1
- 208000000587 small cell lung carcinoma Diseases 0.000 description 1
- 235000011076 sorbitan monostearate Nutrition 0.000 description 1
- 239000001587 sorbitan monostearate Substances 0.000 description 1
- 229940035048 sorbitan monostearate Drugs 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- MHXBHWLGRWOABW-UHFFFAOYSA-N tetradecyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCCCCCCCCCCCCC MHXBHWLGRWOABW-UHFFFAOYSA-N 0.000 description 1
- 229960001722 verapamil Drugs 0.000 description 1
- 239000003871 white petrolatum Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Abstract
Description
技术领域
本发明属于医药用途领域,特别涉及一种硝基苯甲酸类化合物在制备治疗肿瘤的药物中的应用。
背景技术
恶性肿瘤是危害人类健康的重大疾病之一。常见的恶性肿瘤包括肺癌、胃癌、乳腺癌、结肠直肠癌、肝癌、食管癌、淋巴癌和前列腺癌等。恶性肿瘤的种类繁多,每种肿瘤的致病机理、治疗手段和所用药物都存在显著差异。
在肿瘤的治疗过程中,多种微管抑制剂已被用于一线治疗肿瘤,如紫杉醇用于治疗卵巢癌、乳腺癌、肺癌、大肠癌及黑色素瘤等,长春新碱用于治疗急性白血病、恶性淋巴瘤、生殖细胞肿瘤、小细胞肺癌及乳腺癌等,又如CN105012307B公开的IMB5046化合物作为微管抑制剂用于治疗皮肤鳞癌、纤维肉瘤、结直肠腺癌、肺腺癌、大细胞肺癌、肝癌、食管鳞癌、胰腺癌、卵巢腺癌。但是现有技术没有公开其他类的硝基苯甲酸类化合物是否也具有抗肿瘤的活性。
发明内容
针对上述技术问题,本发明提供另一类硝基苯甲酸类化合物其也可以用于制备治疗肿瘤。
本发明其中一个技术方案提供一种式一所示的硝基苯甲酸类化合物在制备用于治疗肿瘤的药物中的应用,
其中,X为NH、CH2或O;Y为NH或OCH2,R1为稠环基或取代稠环基,所述取代稠环基被一个或多个选自C1-6烷基、卤素、C1-6烷氧基、三氟甲氧基、三氟甲基、氨基、硝基或氰基的取代基取代。
进一步改进的方案中,X为O。
进一步改进的方案中,Y为OCH2。
进一步改进的方案中,所述稠环基选自以下结构:
进一步改进的方案中,所述取代稠环基被一个或多个选自甲基、Cl的取代基取代。
进一步改进的方案中,式一所示的硝基苯甲酸类化合物的结构如下:
其中,IMB5476的分子式:C19H17ClN4O5,CAS号:877979-65-2,分子量:416.8241。
进一步改进的方案中,式一所示的硝基苯甲酸类化合物的结构如下:
其中,IMB5117的分子式:C19H18ClN3O5,CAS号:1110832-36-4,分子量:403.82541。
进一步改进的方案中,式一所示的硝基苯甲酸类化合物的结构如下:
其中,IMB5141的分子式:C20H20N4O5,CAS号:1090416-74-2,分子量:396.4062。
进一步改进的方案中,所述硝基苯甲酸类化合物可以和药学上可接受的载体制备成药物组合物。
制成的药物组合物可以通过口服、经皮、经肌肉、皮下等方式给药。
当口服用药时,本发明提供的硝基苯甲酸类化合物可制成任意口服可接受的制剂形式,包括但不限于片剂、胶囊等。其中,片剂使用的载体一般包括乳糖和玉米淀粉,另外也可加入润滑剂如硬脂酸镁。胶囊使用的稀释剂一般包括乳糖和干燥玉米淀粉。任选地,以上口服制剂形式中还可加入一些甜味剂、芳香剂或着色剂。
当皮肤局部施用时,本发明提供的硝基苯甲酸类化合物可制成适当的软膏或霜剂等制剂形式,其中将活性成分悬浮或溶解于一种或多种载体中。软膏制剂可使用的载体包括但不限于:矿物油、液体凡士林、白凡士林、丙二醇、聚氧化乙烯、聚氧化丙烯、乳化蜡和水;霜剂可使用的载体包括但不限于:矿物油、脱水山梨糖醇单硬脂酸酯、吐温60、十六烷酯蜡、十六碳烯芳醇、2-辛基十二烷醇、苄醇和水。
本发明式I所示提供的硝基苯甲酸类化合物还可以无菌注射制剂形式用药,包括无菌注射水或油悬浮液或无菌注射溶液,也可以是冻干形式。其中,可使用的载体和溶剂包括水、林格氏溶液和等渗氯化钠溶液。另外,灭菌的非挥发油也可用作溶剂或悬浮介质,如单甘油酯或二甘油酯。
进一步改进的方案中,所述肿瘤为多药耐药肿瘤。
进一步改进的方案中,所述肿瘤选自皮肤鳞癌、纤维肉瘤、结直肠腺癌、肺癌、大细胞肺癌、肝癌、乳腺癌、胰腺癌、神经内分泌瘤或黑色素瘤中的一种。
进一步改进的方案中,所述肿瘤选自大细胞肺癌、神经内分泌瘤或黑色素瘤。
本发明的有益效果在于:本发明提供的硝基苯甲酸类化合物对多种肿瘤均具有非常好的细胞毒活性,尤其对大细胞肺癌、神经内分泌瘤和黑色素瘤表现出更好的细胞毒活性。且该类硝基苯甲酸类化合物对ATPase酶活性影响较小,因此该类苯甲酸类化合物在细胞内的浓度越高,对细胞杀伤活性更强,尤其对多药耐药肿瘤具有更好的疗效。
具体实施方式
试验实施例1:硝基苯甲酸类化合物对不同来源肿瘤细胞的细胞毒作用
MTT(四甲基偶氮唑盐)法检测化合物IMB5476、IMB5117和IMB5141对培养细胞的细胞毒活性。人皮肤鳞癌A-431细胞、人纤维肉瘤HT-1080细胞、人结直肠腺癌HT-29细胞、人肺癌A549细胞、人大细胞肺癌NCI-H460细胞、人肝癌SMMC-7721细胞、人乳腺癌MCF7细胞、人胰腺癌PANC-1细胞、人神经内分泌瘤BON-1细胞、人皮肤黑色素瘤SK-MEL-28细胞用含10%胎牛血清(Gibco BRL Inc.)、2mM谷氨酰胺、100μg/mL链霉素和100U/mL青霉素的RPMI-1640培养基(Gibco BRL Inc.)在37℃含5%CO2的培养箱(Thermo Scientific)中培养。以上肿瘤细胞株均为常见细胞株,本室保存,也可从商业途径如ATCC细胞库(Rockville,MD,USA)、国家实验细胞资源共享平台等购得。取对数生长期的细胞消化计数,按4000个细胞/孔铺于96孔板,培养24小时后,加入不同浓度的化合物(百灵威化学技术有限公司),每个药物浓度设3个平行孔。继续培养48小时后,每孔加入以PBS溶解的5mg/mL的MTT(Amresco,Ohio,USA)20μL,37℃继续培养4小时后,吸弃上清,加入150μL二甲基亚砜,室温下摇床振摇15分钟,酶标仪(Thermo Labsystems,Multiskan MK3)上测定570nm的光吸收值A。每次实验均设无药对照孔和无细胞空白孔各3孔。按公式:抑制率%=(A对照组-A给药组)/(A对照组-A空白组)×100%计算药物对细胞的增殖抑制率并计算半数抑制浓度(IC50),结果见表1。
表1 三种化合物对肿瘤细胞的细胞毒活性
从表中可以得出,化合物IMB5476对多种肿瘤都有非常好的细胞毒活性,尤其对大细胞肺癌、神经内分泌瘤和黑色素瘤表现出更好的细胞毒活性。三种化合物中IMB5476对人大细胞肺癌细胞的细胞毒活性是IMB5117的2.8倍,是IMB5141的10.4倍。
试验实施例2:化合物对耐药细胞株的细胞毒活性分析
人鳞癌KB及KB来源的多药耐药细胞KBV200来自中国医学科学院药物研究所。以上细胞均用含10%胎牛血清、2mM谷氨酰胺、100μg/mL链霉素和100U/mL青霉素的RPMI-1640培养基在37℃含5%CO2的培养箱中培养;培养KBV200细胞时添加200nM的长春新碱,实验前在不含长春新碱的培养基中培养3天。MTT法比较IMB5476对耐药细胞及其亲本细胞的细胞毒活性,同时以长春新碱及紫杉醇为对照,检测方法如试验实施例1所述,以耐药细胞株与亲本细胞株的IC50比值计算耐药指数。结果如表2所示。
表2 IMB5476对肿瘤耐药细胞株的细胞毒活性
从表2中可以得出,耐药细胞KBV200和亲本细胞KB对IMB5476的敏感性较为接近,而KBV200细胞对长春新碱及紫杉醇表现出耐药,与KB细胞相比耐药指数分别为16.05和4.78。
试验实施例3:P-糖蛋白ATPase活性分析
P-糖蛋白底物会诱导P-糖蛋白ATPase活性的增加,运用P-糖蛋白发光检测试剂盒(Promega Corporation,Madison,Wisconsin,USA)分析IMB5476对P-糖蛋白ATPase活性的影响。检测依操作手册进行,参照CN105012307公开的方法测定化合物IMB5476对P-糖蛋白ATPase活性的影响,结果如表3所示。
表3 化合物IMB5476对P-糖蛋白ATPase活性的影响
从表中可以看出,化合物IMB5476对ATPase酶活性影响显著小于阳性化合物维拉帕米。这一结果表明IMB5476并非P-糖蛋白的底物,P-糖蛋白难以将IMB5476外排到细胞外,IMB5476在抗多药耐药肿瘤方面有较好的应用前景。
Claims (4)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010203050.5A CN111297870B (zh) | 2020-03-20 | 2020-03-20 | 硝基苯甲酸类化合物在制备治疗肿瘤的药物中的应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010203050.5A CN111297870B (zh) | 2020-03-20 | 2020-03-20 | 硝基苯甲酸类化合物在制备治疗肿瘤的药物中的应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN111297870A CN111297870A (zh) | 2020-06-19 |
CN111297870B true CN111297870B (zh) | 2021-03-26 |
Family
ID=71145841
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202010203050.5A Expired - Fee Related CN111297870B (zh) | 2020-03-20 | 2020-03-20 | 硝基苯甲酸类化合物在制备治疗肿瘤的药物中的应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN111297870B (zh) |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105012307A (zh) * | 2015-07-08 | 2015-11-04 | 中国医学科学院医药生物技术研究所 | Imb5046化合物在制备抗肿瘤药物中的用途 |
CN107334767A (zh) * | 2017-06-08 | 2017-11-10 | 中国医学科学院医药生物技术研究所 | 一种哒嗪酮类化合物在肿瘤治疗中的应用 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2014071031A1 (en) * | 2012-11-01 | 2014-05-08 | Incyte Corporation | Tricyclic fused thiophene derivatives as jak inhibitors |
CN109081808B (zh) * | 2018-09-11 | 2020-08-04 | 济南大学 | 一类含有四氢异喹啉结构的酰基苯胺类化合物、用途及其制备方法 |
-
2020
- 2020-03-20 CN CN202010203050.5A patent/CN111297870B/zh not_active Expired - Fee Related
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105012307A (zh) * | 2015-07-08 | 2015-11-04 | 中国医学科学院医药生物技术研究所 | Imb5046化合物在制备抗肿瘤药物中的用途 |
CN107334767A (zh) * | 2017-06-08 | 2017-11-10 | 中国医学科学院医药生物技术研究所 | 一种哒嗪酮类化合物在肿瘤治疗中的应用 |
Non-Patent Citations (2)
Title |
---|
A Novel Nitrobenzoate Microtubule Inhibitor that Overcomes Multidrug Resistance Exhibits Antitumor Activity;Yan-Bo Zheng et al;《Scientific Reports》;20160811;第6卷(第31472期);第1-12页 * |
新型微管抑制剂IMB5046 的合成及抗血管生成活性;郑艳波;《药学学报》;20191231;第54卷(第3期);第469−474页 * |
Also Published As
Publication number | Publication date |
---|---|
CN111297870A (zh) | 2020-06-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2316326C2 (ru) | Способ и композиция для лечения ракового заболевания, тозилат и фармацевтически приемлемые соли n-(4-хлор-3-(трифторметил)фенил)-n'-(4-(2-(n-метилкарбамоил)-4-пиридилокси)фенил)мочевины | |
EP2809324B1 (en) | Cdk8/cdk19 selective inhibitors and their use in anti-metastatic and chemopreventive methods for cancer | |
AU2012361581B2 (en) | Effect potentiator for antitumor agents | |
US8691870B2 (en) | Use of isothiocyanates for treating cancer | |
CN108774219B (zh) | 抑制pd-1/pd-l1的小分子化合物及其用途 | |
CN111297870B (zh) | 硝基苯甲酸类化合物在制备治疗肿瘤的药物中的应用 | |
KR100468271B1 (ko) | 피페라진옥시란유도체를포함하는약제학적조성물 | |
CN115105603B (zh) | MCL-1抑制剂和BCL-xL抑制剂在制备治疗实体肿瘤药物中的应用 | |
EP2902028A1 (en) | Drug composition for treating tumors and application thereof | |
CN105012307B (zh) | Imb5046化合物在制备抗肿瘤药物中的用途 | |
CN111821303B (zh) | 沃替西汀及其盐在制备抗肿瘤药物中的应用 | |
CN112999221B (zh) | 一种三氮唑类化合物在制备抗肿瘤药物中的应用 | |
JP2022528454A (ja) | A-NOR-5αアンドロスタン薬物と抗がん薬物との併用 | |
JP7395642B2 (ja) | モノアミジン及びジアミジンのエンド-エキソヌクレアーゼ阻害剤とエンド-エキソヌクレアーゼ活性を阻害する方法 | |
CN112915087B (zh) | 一种基于5-羧基-8-羟基喹啉的抗肿瘤药物增敏剂及其应用 | |
CN111153817B (zh) | 苯氧基-n-苯基苯胺衍生物及其应用 | |
TW200815329A (en) | Dihydrobenzoquinone compounds | |
CN104619324A (zh) | 治疗肿瘤的组合药物及其应用 | |
CN116251107A (zh) | Z-2-366在用于制备抑制eEF2K表达的药物中的应用 | |
Chatterji et al. | Microtubules as Anti-Cancer Drug Targets | |
CN113069451A (zh) | 一种吡咯-2-磺酰胺化合物的制备方法及其在制备抗肿瘤药物中的应用 | |
CN104619325A (zh) | 治疗肿瘤的组合药物及其应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
CF01 | Termination of patent right due to non-payment of annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20210326 |